NCT05226507CompletedPhase 1
NXP800 in subjects with Ovarian Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jun 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- First submitted
- 18 Dec 2023
- Start date
- 1 Apr 2024
- Lead sponsor
- Nuvectis Pharma Inc.
- Diseases
- Ovarian cancer
- NCT number
- NCT05226507
- EU CT number
- 2023-509150-64-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 8
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vall D'hebron Institut De Recerca Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Clinica Universidad de Navarra Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Clínica Universidad de navarra Coordinator of this site? Confirm its status | Pamplona | Spain | Completed |
| Hospital Clinico Universitario de Valencia Coordinator of this site? Confirm its status | Valencia | Spain | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.